Allianz Asset Management Gmb H Intercept Pharmaceuticals, Inc. Transaction History

Allianz Asset Management Gmb H

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$9.99 - $18.71 $326,673 - $611,817	32,700 New	32,700 $606,000
Q4 2020 Feb 16, 2021	SELL	$24.48 - $42.47 $255,595 - $443,429	-10,441 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$39.09 - $53.44 $215,620 - $294,775	5,516 Added 112.0%	10,441 $433,000
Q2 2020 Aug 14, 2020	SELL	$46.7 - $92.04 $130,713 - $257,619	-2,799 Reduced 36.24%	4,925 $236,000
Q1 2020 May 14, 2020	SELL	$48.35 - $118.68 $359,772 - $883,097	-7,441 Reduced 49.07%	7,724 $486,000
Q4 2019 Feb 13, 2020	BUY	$57.36 - $124.1 $30,114 - $65,152	525 Added 3.59%	15,165 $1.88 Million
Q3 2019 Nov 13, 2019	BUY	$58.69 - $80.46 $528 - $724	9 Added 0.06%	14,640 $966,000
Q2 2019 Aug 08, 2019	BUY	$77.77 - $120.68 $251,974 - $391,003	3,240 Added 28.44%	14,631 $1.16 Million
Q1 2019 May 13, 2019	BUY	$91.83 - $120.68 $273,010 - $358,781	2,973 Added 35.32%	11,391 $1.27 Million
Q4 2018 Feb 14, 2019	SELL	$85.79 - $126.46 $64,428 - $94,971	-751 Reduced 8.19%	8,418 $829,000
Q3 2018 Nov 13, 2018	BUY	$88.49 - $127.55 $121,142 - $174,615	1,369 Added 17.55%	9,169 $1.16 Million
Q4 2017 Feb 13, 2018	BUY	$58.2 - $72.76 $162,960 - $203,728	2,800 Added 56.0%	7,800 $456,000
Q3 2017 Nov 13, 2017	SELL	$57.01 - $118.75 $158,031 - $329,175	-2,772 Reduced 35.67%	5,000 $290,000
Q2 2017 Aug 14, 2017	SELL	N/A	-100 Reduced 1.27%	7,772 $953,000
Q1 2017 Apr 17, 2019	BUY	N/A	277 Added 3.65%	7,872 $889,000
Q4 2016 Apr 17, 2019	SELL	N/A	-2,164 Reduced 22.17%	7,595 $825,000
Q3 2016 Apr 17, 2019	BUY	N/A	9,759	9,759 $1.57 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.